Malaghan Institute of Medical Research

Third-generation anti-CD19 CAR T-cells demonstrate efficacy without neurotoxicity in B-cell lymphoma phase 1 clinical trial

A phase 1 clinical trial demonstrates the efficacy of third-generation anti-CD19 CAR T-cells in treating relapsed or refractory B-cell non-Hodgkin lymphomas without causing neurotoxicity. The study also shows a robust response rate of 52% and improved safety profile compared to previous CAR T-cell therapies.

SourceMalaghan Institute of Medical Research·JournalBlood·TypeExperimental study·DateDec 11, 2023

Discovery points to the skin as ‘ground zero’ for allergic disease

Research by Malaghan Institute of Medical Research finds dendritic cells in the skin behave differently than counterparts elsewhere, playing a key role in allergy onset. Unique IL-13 signals may trigger constant immune responses, leading to allergic disease.

SourceMalaghan Institute of Medical Research·JournalNature Immunology·TypeExperimental study·DateDec 1, 2021